Adverse Event Management in HR+/HER2– Advanced Breast Cancer: PI3K/AKT/PTEN Pathway - Episode 1

Insights on Biomarker Testing in HR+/HER2- Advanced Breast Cancer

, ,

Panelists discuss how biomarker testing plays a critical role in hormone receptor–positive, HER2-negative advanced breast cancer, emphasizing the timing of testing, the relevance of specific genomic assays, and the significant impact on prognosis and treatment decisions.

Now Viewing
EP. 1: Insights on Biomarker Testing in HR+/HER2- Advanced Breast Cancer
EP. 2: Role of PI3K/AKT/PTEN Pathway in HR+/HER2- Advanced Breast Cancer
EP. 3: Overview of the CAPItello-291 Trial
EP. 4: Clinical Experience with Capivasertib
EP. 5: Adverse Event Management: Strategies for Reducing Diarrhea Risk in Capivasertib Therapy
EP. 6: Managing Capivasertib Side Effects: Strategies for Educating, Monitoring, and Addressing Rash and Hyperglycemia
EP. 7: Best Practices in Managing Patients on Capivasertib

Video content above is prompted by the following:

  1. Please discuss the role of biomarker testing in hormone receptor–positive, HER2-negative advanced breast cancer.
  • At what point during the disease course do you test for biomarkers?
  • What are the most clinically relevant genomic tests or biomarker assays, and how do the results influence prognosis and treatment?

Related Content:

Adverse Event Management in HR+/HER2– Advanced Breast Cancer: PI3K/AKT/PTEN Pathway
Best Practices in Managing Patients on Capivasertib
Managing Capivasertib Side Effects: Strategies for Educating, Monitoring, and Addressing Rash and Hyperglycemia
Adverse Event Management: Strategies for Reducing Diarrhea Risk in Capivasertib Therapy